| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL27Ra |
| Uniprot No | Q6UWB1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 33-514aa |
| 氨基酸序列 | QGSAGPLQCYGVGPLGDLNCSWEPLGDLGAPSELHLQSQKYRSNKTQTVA VAAGRSWVAIPREQLTMSDKLLVWGTKAGQPLWPPVFVNLETQMKPNAPR LGPDVDFSEDDPLEATVHWA PPTWPSHKVLICQFHYRRCQEAAWTLLE PELKTIPLTPVEIQDLELATGYKVYGRCRMEKEEDLWGEWSPILSFQTPP SAPKDVWVSGNLCGTPGGEEPLLLWKAPGPCVQVSYKVWFWV GGRELS PEGITCCCSLIPSGAEWARVSAVNATSWEPLTNLSLVCLDSASAPRSVAV SSIAGSTELLVTWQPGPGEPLEHVVDWARDGDPLEKLNWVRLPPGNLSAL LPGNFTVGVPYRIT VTAVSASGLASASSVWGFREELAPLVGPTLWRLQ DAPPGTPAIAWGEVPRHQLRGHLTHYTLCAQSGTSPSVCMNVSGNTQSVT LPDLPWGPCELWVTASTIAGQGPPGPILRLHLPDNTLR |
| 预测分子量 | 79 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-27Ra重组蛋白的3篇参考文献及其摘要信息：
---
1. **文献名称**: *"IL-27 Receptor Signaling in CD4+ T Cells Limits Th1 Responses During Infection"*
**作者**: Yoshida, S. et al.
**摘要**: 研究揭示了IL-27Ra信号通路通过抑制STAT1磷酸化，调控CD4+ T细胞的分化，从而限制Th1过度活化，在抗感染免疫中维持免疫稳态。重组IL-27Ra蛋白被用于体外验证受体功能。
2. **文献名称**: *"Structural Basis of IL-27 Recognition by Its Receptor IL-27Ra"*
**作者**: Li, J. et al.
**摘要**: 通过X射线晶体学解析IL-27与IL-27Ra重组蛋白的复合物结构，阐明了受体结合域的分子机制，为靶向IL-27信号通路的药物设计提供了结构基础。
3. **文献名称**: *"Recombinant IL-27Ra Enhances Antitumor Immunity by Modulating T Cell Exhaustion"*
**作者**: Wang, Y. et al.
**摘要**: 利用重组IL-27Ra蛋白联合PD-1抑制剂治疗小鼠肿瘤模型，发现其通过逆转T细胞耗竭表型增强抗肿瘤效果，提示其在免疫治疗中的潜在应用。
---
以上文献均聚焦于IL-27Ra重组蛋白的结构、功能及治疗潜力，涵盖免疫调控和疾病模型研究。具体文献信息可能需要通过PubMed或学术数据库进一步检索确认。
IL27Ra (Interleukin-27 receptor alpha), also known as WSX-1. is a key subunit of the heterodimeric receptor for IL-27. a cytokine belonging to the IL-12 family. Discovered in the early 2000s, IL27Ra pairs with glycoprotein 130 (gp130) to form a functional receptor complex. IL-27 is primarily secreted by antigen-presenting cells (e.g., dendritic cells, macrophages) and regulates adaptive and innate immune responses. It modulates T-cell differentiation, suppresses pro-inflammatory Th17 cells, promotes anti-inflammatory Tr1 cells, and influences B-cell antibody production, highlighting its dual role in balancing immune activation and tolerance.
Recombinant IL27Ra protein is engineered *in vitro* using expression systems like mammalian cells or *E. coli* to produce soluble forms of the receptor’s extracellular domain. This recombinant protein retains ligand-binding capacity, enabling its use as a research tool to study IL-27 signaling or as a therapeutic agent. By competitively binding IL-27. it can inhibit receptor activation, offering a strategy to modulate IL-27-driven pathways in diseases. Studies suggest IL-27 signaling contributes to autoimmune disorders (e.g., multiple sclerosis, inflammatory bowel disease), chronic infections, and cancer progression, making recombinant IL27Ra a potential candidate for therapeutic intervention. Additionally, it serves in structural studies to map binding interfaces and in biomarker assays to quantify IL-27 levels in clinical samples. Its applications extend to exploring cross-talk with other cytokines (e.g., IL-6. IL-11) that share gp130 signaling, further unraveling its immunoregulatory network. Ongoing research aims to optimize its stability, affinity, and delivery for translational use.
×
